Discovery of isoxazole analogues of sazetidine-A as selective α4β2-nicotinic acetylcholine receptor partial agonists for the treatment of depression

Journal of Medicinal Chemistry

Volumn 54, Issue 20, 2011, Pages 7280-7288

  Liu, Jianhua ^a   Yu, Li Fang ^a   Eaton, J Brek ^b   Caldarone, Barbara ^c   Cavino, Katie ^c   Ruiz, Christina ^c   Terry, Matthew ^c   Fedolak, Allison ^c   Wang, Daguang ^c   Ghavami, Afshin ^c   Lowe, David A ^c   Brunner, Dani ^c,d   Lukas, Ronald J ^b   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c PSYCHOGENICS INC   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 [5 (2 AZETIDINYLMETHOXY) 3 PYRIDYL] 3 ISOXAZOLYL]ETHANOL; 3 [5 (2 AZETIDINYLMETHOXY) 3 PYRIDYL] 3 ISOXAZOLYLMETHANOL; 3 [5 [5 (2 AZETIDINYLMETHOXY) 3 PYRIDYL] 3 ISOXAZOLYL] 1 PROPANOL; 4 AMINOBUTYRIC ACID RECEPTOR; ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; BENZODIAZEPINE RECEPTOR; CYTOCHROME P450; DOPAMINE RECEPTOR; HISTAMINE RECEPTOR; ISOXAZOLE DERIVATIVE; MUSCARINIC RECEPTOR; NEUROTRANSMITTER TRANSPORTER; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA3BETA4; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR ALPHA4BETA2 STIMULATING AGENT; OPIATE RECEPTOR; PARTIAL AGONIST; POTASSIUM CHANNEL HERG; SAZETIDINE A DERIVATIVE; SEROTONIN RECEPTOR; SERTRALINE; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; FORCED SWIMMING TEST; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; MALE; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; RECEPTOR OCCUPANCY;

ANIMALS; ANTIDEPRESSIVE AGENTS; AZETIDINES; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; BLOOD PROTEINS; DRUG PARTIAL AGONISM; HUMANS; ISOXAZOLES; MICE; MICROSOMES, LIVER; NICOTINIC AGONISTS; PROTEIN BINDING; PYRIDINES; RATS; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80054885415     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200855b     Document Type: Article

References (39)

1. World Health Organization. Mental health and development: targeting people with mental health conditions as a vulnerable group. WHO Press: Geneva, Switzerland, 2010.
2. Henn, F.; Vollmayr, B.; Sartorius, A. Mechanisms of depression: the role of neurogenesis Drug Discovery Today: Dis. Mech. 2004, 1, 407-411 (Pubitemid 41128943)
3. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. WHO Press: Geneva, Switzerland, 2009.
4. Reeves, R. R.; Ladner, M. E. Antidepressant-induced suicidality: an update CNS Neurosci. Ther. 2010, 16, 227-234
5. Berton, O.; Nestler, E. J. New approaches to antidepressant drug discovery: beyond monoamines Nat. Rev. Neurosci. 2006, 7, 137-151 (Pubitemid 43151600)
6. Zheng, C. J.; Han, L. Y.; Yap, C. W.; Ji, Z. L.; Cao, Z. W.; Chen, Y. Z. Therapeutic targets: progress of their exploration and investigation of their characteristics Pharmacol. Rev. 2006, 58, 259-279
7. Abel, T.; Zukin, R. S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders Curr. Opin. Pharmacol. 2008, 8, 57-64
8. Schroeder, F. A.; Lin, C. L.; Crusio, W. E.; Akbarian, S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse Biol. Psychiatry 2007, 62, 55-64 (Pubitemid 46898220)
9. Miyamoto, Y.; Yamada, K.; Noda, Y.; Mori, H.; Mishina, M.; Nabeshima, T. Lower sensitivity to stress and altered monoaminergic neuronal function in mice lacking the NMDA receptor epsilon 4 subunit J. Neurosci. 2002, 22, 2335-2342 (Pubitemid 35386532)
10. Shytle, R. D.; Silver, A. A.; Lukas, R. J.; Newman, M. B.; Sheehan, D. V.; Sanberg, P. R. Nicotinic acetylcholine receptors as targets for antidepressants Mol. Psychiatry 2002, 7, 525-535
11. Buckley, M. J.; Surowy, C.; Meyer, M.; Curzon, P. Mechanism of action of A-85380 in an animal model of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28, 723-730 (Pubitemid 38987398)
12. Ferguson, S. M.; Brodkin, J. D.; Lloyd, G. K.; Menzaghi, F. Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression Psychopharmacology (Berlin) 2000, 152, 295-303
13. Rabenstein, R. L.; Caldarone, B. J.; Picciotto, M. R. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice Psychopharmacology (Berlin) 2006, 189, 395-401 (Pubitemid 44772820)
14. Caldarone, B. J.; Harrist, A.; Cleary, M. A.; Beech, R. D.; King, S. L.; Picciotto, M. R. High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation Biol. Psychiatry 2004, 56, 657-664 (Pubitemid 39446847)
15. Picciotto, M. R.; Zoli, M.; Lena, C.; Bessis, A.; Lallemand, Y.; Le Novere, N.; Vincent, P.; Pich, E. M.; Brulet, P.; Changeux, J. P. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain Nature 1995, 374, 65-67
16. Romanelli, M. N.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential ChemMedChem 2007, 2, 746-767
17. Gotti, C.; Clementi, F.; Fornari, A.; Gaimarri, A.; Guiducci, S.; Manfredi, I.; Moretti, M.; Pedrazzi, P.; Pucci, L.; Zoli, M. Structural and functional diversity of native brain neuronal nicotinic receptors Biochem. Pharmacol. 2009, 78, 703-711
18. Zwart, R.; Carbone, A. L.; Moroni, M.; Bermudez, I.; Mogg, A. J.; Folly, E. A.; Broad, L. M.; Williams, A. C.; Zhang, D.; Ding, C.; Heinz, B. A.; Sher, E. Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors Mol. Pharmacol. 2008, 73, 1838-1843 (Pubitemid 351724371)
19. Xiao, Y.; Fan, H.; Musachio, J. L.; Wei, Z. L.; Chellappan, S. K.; Kozikowski, A. P.; Kellar, K. J. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them Mol. Pharmacol. 2006, 70, 1454-1460 (Pubitemid 44435998)
20. Kozikowski, A. P.; Eaton, J. B.; Bajjuri, K. M.; Chellappan, S. K.; Chen, Y.; Karadi, S.; He, R.; Caldarone, B.; Manzano, M.; Yuen, P. W.; Lukas, R. J. Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2- ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression ChemMedChem 2009, 4, 1279-1291
21. Liu, J.; Eaton, J. B.; Caldarone, B.; Lukas, R. J.; Kozikowski, A. P. Chemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as alpha4beta2-nicotinic acetylcholine receptor-selective partial agonists J. Med. Chem. 2010, 53, 6973-6985
22. Tapadar, S.; He, R.; Luchini, D. N.; Billadeau, D. D.; Kozikowski, A. P. Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity Bioorg. Med. Chem. Lett. 2009, 19, 3023-3026
23. Huang, Q.; Mao, J.; Wan, B.; Wang, Y.; Brun, R.; Franzblau, S. G.; Kozikowski, A. P. Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles J. Med. Chem. 2009, 52, 6757-6767
24. Lilienkampf, A.; Pieroni, M.; Wan, B.; Wang, Y.; Franzblau, S. G.; Kozikowski, A. P. Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis: a potent and selective series for further drug development J. Med. Chem. 2010, 53, 678-688
25. Wei, Z. L.; Petukhov, P. A.; Bizik, F.; Teixeira, J. C.; Mercola, M.; Volpe, E. A.; Glazer, R. I.; Willson, T. M.; Kozikowski, A. P. Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis, and effects on cardiomyocyte differentiation J. Am. Chem. Soc. 2004, 126, 16714-16715 (Pubitemid 40069477)
26. Gotti, C.; Clementi, F.; Fornari, A.; Gaimarri, A.; Guiducci, S.; Manfredi, I.; Moretti, M.; Pedrazzi, P.; Pucci, L.; Zoli, M. Structural and functional diversity of native brain neuronal nicotinic receptors Biochem. Pharmacol. 2009, 78, 703-711
27. Nicolazzo, J. A.; Charman, S. A.; Charman, W. N. Methods to assess drug permeability across the blood-brain barrier J. Pharm. Pharmacol. 2006, 58, 281-293 (Pubitemid 43344570)
28. Fan, Y.; Unwalla, R.; Denny, R. A.; Di, L.; Kerns, E. H.; Diller, D. J.; Humblet, C. Insights for predicting blood-brain barrier penetration of CNS targeted molecules using QSPR approaches J. Chem. Inf. Model. 2010, 50, 1123-1133
29. Romanelli, M. N.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential ChemMedChem 2007, 2, 746-767
30. Lukas, R. J.; Fryer, J. D.; Eaton, J. B.; Gentry, C. L. Some methods for studies of nicotinic acetylcholine receptor pharmacology. In Nicotinic Receptors and the Nervous System; Levin, E. D., Ed.; CRC Press: Boca Raton, FL, 2002; pp 3-27.
31. Paterson, N. E.; Min, W.; Hackett, A.; Lowe, D.; Hanania, T.; Caldarone, B.; Ghavami, A. The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34, 1455-1464
32. Turner, J. R.; Castellano, L. M.; Blendy, J. A. Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior J. Pharmacol. Exp. Ther. 2010, 334, 665-672
33. Kozikowski, A. P.; Eaton, J. B.; Bajjuri, K. M.; Chellappan, S. K.; Chen, Y.; Karadi, S.; He, R.; Caldarone, B.; Manzano, M.; Yuen, P. W.; Lukas, R. J. Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2- ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression ChemMedChem 2009, 4, 1279-1291
34. Porsolt, R. D.; Bertin, A.; Jalfre, M. Behavioral despair in mice: a primary screening test for antidepressants Arch. Int. Pharmacodyn. Ther. 1977, 229, 327-336 (Pubitemid 8225714)
35. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups J. Med. Chem. 2006, 49, 5029-5046 (Pubitemid 44260200)
36. Lin, N.-H.; He, Y.; Li, Y.; Holladay, M. W.; Ryther, K. 3-Pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission. U.S. Patent 5629325, May 13, 1997.
37. Lukas, R. J.; Norman, S. A.; Lucero, L. Characterization of nicotinic acetylcholine receptors expressed by cells of the SH-SY5Y human neuroblastoma clonal line Mol. Cell Neurosci. 1993, 4, 1-12 (Pubitemid 23070130)
38. Eaton, J. B.; Peng, J. H.; Schroeder, K. M.; George, A. A.; Fryer, J. D.; Krishnan, C.; Buhlman, L.; Kuo, Y. P.; Steinlein, O.; Lukas, R. J. Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells Mol. Pharmacol. 2003, 64, 1283-1294 (Pubitemid 37532218)
39. Caldarone, B. J.; Wang, D.; Paterson, N. E.; Manzano, M.; Fedolak, A.; Cavino, K.; Kwan, M.; Hanania, T.; Chellappan, S. K.; Kozikowski, A. P.; Olivier, B.; Picciotto, M. R.; Ghavami, A. Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380 Psychopharmacology (Berlin) 2011, 217, 199-210